Omnipaque and urografin in arthrography of the knee.
The first experience with Omnipaque in arthrography of the knee in patients is reported. Forty arthrographies were performed using either Omnipaque 350 mg I/ml or Urografin 370 mg I/ml at random. The low-osmolar non-ionic Omnipaque showed a tendency for pain of shorter duration and lower incidence of hydrops. A significantly lower incidence of complaints of tension and swelling and assessed reactive synovitis was demonstrated. Both contrast media produced excellent synovial coating on standard series, but Omnipaque showed a slower decrease in attenuation.
D000293:Adolescent; D000328:Adult; D003287:Contrast Media / Q000009:adverse effects; D003973:Diatrizoate / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D007719:Knee Joint / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D011859:Radiography; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; D007472:Iohexol